arrow
A

Ahmed Aribi

Department of Hematology
H指数:26
被引数:2,424

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation

无残疾生存:老年异基因造血细胞移植的一种新型疾病终点

2026-03-280
PRE
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

异基因造血细胞移植治疗骨髓纤维化受者中中性粒细胞植入期间的肺部表现

2025-09-240
OA
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia

靶向治疗和免疫疗法在TP53突变急性淋巴细胞白血病患者中的疗效

2025-09-010
PRE
Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

门诊Brexucabtagene autoleucel在B细胞急性淋巴细胞白血病和套细胞淋巴瘤中的应用

2025-08-200
PREAI
Outcomes After Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment

基于美法仑的减低强度异基因造血细胞移植在肾功能不全患者中的结局

2025-07-010
PRE
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect

基于美法仑的预处理联合移植后环磷酰胺用于外周血干细胞移植:供者效应

2025-02-270
OA
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
2025-02-200
OAAI
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

真实世界(RW)结局:Brexucabtagene autoleucel(Brexu-Cel)治疗具有高风险特征及既往治疗史患者的复发或难治性B细胞急性淋巴细胞白血病(R/R B-ALL)结局;来自CIBMTR®登记数据的更新证据

BLOOD
IF23.1
2024-11-051
PRE
Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

急性淋巴细胞白血病(ALL)和套细胞淋巴瘤(MCL)门诊输注Brexucabtagene Autoleucel(brexu-cel)安全且可行

BLOOD
IF23.1
2024-11-050
PRE
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation
2024-10-010
PRE
Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

对CD19CAR T细胞治疗有反应的复发/难治性b-all成人患者进行第一次和第二次同种异体移植的巩固

2024-08-013
PRE
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia
2024-05-281
PRE
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant
2024-02-082
OAAI
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma
2023-09-0512
OA
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab
2023-05-015
OAAI
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions
2023-03-168
OAAI